Fair Value of Financial Assets and Liabilities (Details) - Schedule of Fair Value on a Recurring Basis - Fair Value, Inputs, Level 3 [Member] - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Short-term investment at December 31, 2022	$ 13
Change in fair value of investment	(12)
Short-term investment at September 30, 2023	1
Notes receivable at fair value, current portion at December 31, 2022	7,474
Collection of principal outstanding	(750)
Note receivable, Convergent Therapeutics, non-current portion	(250)
Unrealized loss on note receivable	(212)
Accrued interest receivable	74
Notes receivable at fair value, current portion at September 30, 2023	6,336
Notes receivable at fair value, non-current portion at December 31, 2022	1,100
Note receivable, Convergent Therapeutics, non-current portion	250
Accrued interest receivable	22
Notes receivable at fair value, non-current portion at September 30, 2023	$ 1,372